Transdermal patches are administered through the skin using adhesive patches, which can control the release of the drug for several hours to several days, prolong the effective time of action, reduce the number of medications, maintain a relatively constant drug concentration in blood, reduce side effects, and avoid the possible first-pass liver effect and gastrointestinal inactivation of oral administration. Novastage Pharmaceuticals, Ltd. adopts its unique transdermal high-barrier formulation technology to establish advantages in improving drug efficacy, reducing drug toxicity, enhancing patient medication compliance, and increasing new drug indications.
One of the advantages of oral film products is that they are easy to be administered and do not need to be swallowed with water. The US FDA evaluated the dosage form as "an irreplaceable new dosage form among traditional oral dosage forms." This useful form of drug delivery is very suitable for pediatric and elderly patients. Among them, the sublingual membrane/buccal membrane directly transports the drug from the sublingual or cheek to the blood vessel without passing through the digestive system, which can deliver the drug to the diseased part of the patient more quickly, and can avoid the first-pass liver effect. Novastage Pharmaceuticals has the high-barrier oral film technology and will devote itself to develop oral film products for young and elderly patients.